Compare Esperance Pharmaceuticals vs Inflabloc Pharmaceuticals
Customers evaluate the quality of Esperance Pharmaceuticals's products using the following success metrics.
Overview
Esperance Pharmaceuticals is 19 yrs old and is based in United States.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Inflabloc Pharmaceuticals is 33 yrs old and is based in United States.
Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.
Demo Video
Leadership
Hector Alila (President)
Willem Spiegel (Chief Financial Officer)
Funding
Investors
Louisiana Funds, Research Corporation Technologies
vSpring Capital, Friedli Corporate Finance
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Esperance Pharmaceuticals has not claimed their profile.
Work for Esperance Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Esperance Pharmaceuticals?
Claim your profile now.
Information not available because Inflabloc Pharmaceuticals has not claimed their profile.
Work for Inflabloc Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Inflabloc Pharmaceuticals?
Claim your profile now.